Oral Linezolid Dosing in Children
For children aged 6 months to 11 years, administer linezolid 10 mg/kg orally every 8 hours (not to exceed 600 mg per dose); for children 12 years and older, administer 600 mg orally every 12 hours. 1
Age-Based Dosing Algorithm
Children Birth to 11 Years
- Dose: 10 mg/kg every 8 hours (PO or IV)
- Maximum single dose: 600 mg
- Rationale: Younger children have faster linezolid clearance compared to adults, requiring more frequent dosing to achieve similar daily AUC values 1
Adolescents ≥12 Years and Adults
- Dose: 600 mg every 12 hours (PO or IV)
- Rationale: By adolescence, clearance values approach adult levels, allowing for standard twice-daily dosing 1
Key Clinical Considerations
Pharmacokinetic Basis: The every-8-hour dosing in younger children is critical because clearance is most rapid in age groups from >1 week to 11 years, resulting in lower single-dose systemic exposure and shorter half-life compared to adults 1. The FDA label explicitly states that similar mean daily AUC values are achieved in pediatric patients dosed every 8 hours relative to adolescents/adults dosed every 12 hours 1.
Bioavailability: Linezolid has approximately 100% oral bioavailability, so no dose adjustment is needed when switching between IV and oral routes 1. The drug may be administered without regard to meals, though high-fat food slightly delays absorption without affecting total exposure 1.
Important Caveats
Neonatal Dosing Exception
For neonates <7 days of age (especially preterm <34 weeks gestational age):
- Start with 10 mg/kg every 12 hours
- Consider increasing to every 8 hours if suboptimal clinical response
- All neonates should receive every 8-hour dosing by 7 days of life 1
Potential Underdosing Risk
Recent pharmacokinetic studies suggest the standard 10 mg/kg every 8 hours (30 mg/kg/day total) may be insufficient for bacteria with MICs ≥2 mg/L 2, 3. For infections with known or suspected pathogens at this MIC threshold, consider:
- Elevated dosing of 35-45 mg/kg/day (divided every 8 hours) to achieve AUC24/MIC ratio ≥100 3
- Therapeutic drug monitoring when available, targeting trough concentrations while avoiding levels >7 mg/L to minimize thrombocytopenia risk 3
Safety Monitoring
The most common adverse effects in pediatric patients include diarrhea (7.8-10.8%), vomiting, and fever 4, 5. Hematologic monitoring is essential, particularly for:
Duration-dependent toxicity: Neurological and hematological adverse effects increase with prolonged treatment duration, particularly beyond 2-4 weeks 7.
Clinical Effectiveness
Linezolid demonstrates excellent efficacy in pediatric populations for:
- Community-acquired pneumonia (92.4% cure rate) 6
- Hospital-acquired pneumonia (90% cure rate) 5
- Catheter-related bacteremia (84.8% cure rate) 5
- Complicated skin and soft tissue infections 8, 9
The drug is particularly valuable for MRSA and other resistant Gram-positive infections, with clinical cure rates comparable to vancomycin but with the advantage of oral bioavailability 5.